Form 8-K - Current report:
SEC Accession No. 0001213900-25-033366
Filing Date
2025-04-18
Accepted
2025-04-18 16:05:37
Documents
16
Period of Report
2025-04-16
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 3.03: Material Modifications to Rights of Security Holders
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0238657-8k_citius.htm   iXBRL 8-K 34126
2 CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK ea023865701ex3-1_citius.htm EX-3.1 14488
3 AMENDMENT TO THE AMENDED AND RESTATED BYLAWS OF CITIUS PHARMACEUTICALS, INC ea023865701ex3-2_citius.htm EX-3.2 2853
4 SUBSCRIPTION AND INVESTMENT REPRESENTATION AGREEMENT, DATED APRIL 17, 2025, BY A ea023865701ex10-1_citius.htm EX-10.1 33305
  Complete submission text file 0001213900-25-033366.txt   278360

Data Files

Seq Description Document Type Size
5 XBRL SCHEMA FILE ctxr-20250416.xsd EX-101.SCH 3026
6 XBRL LABEL FILE ctxr-20250416_lab.xml EX-101.LAB 34239
7 XBRL PRESENTATION FILE ctxr-20250416_pre.xml EX-101.PRE 22366
18 EXTRACTED XBRL INSTANCE DOCUMENT ea0238657-8k_citius_htm.xml XML 3794
Mailing Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016
Business Address 11 COMMERCE DRIVE 1ST FLOOR CRANFORD NJ 07016 (908) 967-6676
Citius Pharmaceuticals, Inc. (Filer) CIK: 0001506251 (see all company filings)

EIN.: 273425913 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 8-K | Act: 34 | File No.: 001-38174 | Film No.: 25850486
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)